Menu Search
Equities

Ovid Therapeutics Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
1OT:MUN

Ovid Therapeutics Inc

Actions
  • Price (EUR)1.35
  • Today's Change0.05 / 3.85%
  • Shares traded370.00
  • 1 Year change+110.94%
  • Beta0.2543
Data delayed at least 15 minutes, as of Feb 11 2026 07:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Ovid Therapeutics Inc. is a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need. It is advancing a pipeline of novel, targeted small-molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. It develops OV329, which is a GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. It also maintains the KCC2 library, which is a portfolio of potential first-in-class direct activators of potassium chloride cotransporter2. Both OV350 and OV4071 are intended for the potential treatment of psychosis associated with neuronal-synuclein diseases (NSD), which include Parkinson’s disease and Lewy body dementia (LBD).

  • Revenue in USD (TTM)6.61m
  • Net income in USD-36.33m
  • Incorporated2014
  • Employees23.00
  • Location
    Ovid Therapeutics Inc441 NINTH AVENUE, 14TH FLOORNEW YORK 10001United StatesUSA
  • Phone+1 (212) 776-4381
  • Fax+1 (302) 636-5454
  • Websitehttps://ovidrx.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.